BAYER AG NA O.N.
Commented by Armin Schulz on April 17th, 2026 | 07:30 CEST
Bayer, MustGrow Biologics, and Yara International: How to Capitalize on the 40% Fertilizer Price Surge in Your Portfolio
Since late February 2026, the war in Iran has blocked the Strait of Hormuz, sending nitrogen fertilizer prices soaring by 40%. While geopolitical shocks are disrupting supply chains, unusual opportunities are emerging for savvy investors. Analysts warn that the shortage of urea and other fertilizers will persist through the end of the year. But it is not just traditional manufacturers benefiting; smart alternative concepts are also stepping into the spotlight. Three completely different players in the agricultural sector could benefit disproportionately from the supply chaos: Bayer, MustGrow Biologics, and Yara International.
Read
Commented by Nico Popp on April 14th, 2026 | 07:15 CEST
Opportunities from the Agricultural Transition: Bayer, Sumitomo, and MustGrow Biologics
Conventional agriculture must rethink its approach: Chemical pesticides are to be reduced and replaced with biological alternatives. Strict regulations, such as the European Union's (EU) Farm-to-Fork Strategy, make this path irreversible and call for a 50% reduction in chemical risks associated with pesticides by 2030. While corporations like Bayer are restructuring their portfolios to be more environmentally friendly, global trading companies like Sumitomo are securing access to novel technologies. A key player in the agricultural transition is the innovative company MustGrow Biologics, which has developed natural plant protection products based on mustard seeds that effectively combat pests in the soil without causing long-term harm to the environment.
Read
Commented by Mario Hose on April 13th, 2026 | 07:30 CEST
100% Profit Potential in Sight: Vidac Pharma's Chance to Double vs Bayer and Evotec
Even in the spring of 2026, the stock market remains highly volatile. The upheavals caused by geopolitical crises have been and remain significant and ever-present. While heavyweights like Bayer are struggling to shake off their legal baggage and Evotec is steering into calmer waters, a stock from the back row is suddenly stepping into the spotlight. Vidac Pharma has also had a few turbulent months, and this is precisely where experienced investors now sense an opportunity. With a current share price of EUR 0.56, the company is poised for a potential recovery, an uptick, and perhaps even a complete revaluation. If the strategy pays off, the EUR 1 mark could be reached. That would be a chance to double their money for bold investors. But what is behind this optimism? In this report, we take a look at the industry giants and analyze not only them but also why, of all three, the one with the smallest market capitalization could develop the greatest momentum. It is about potential breakthroughs in cancer research and a management team that is optimizing many aspects for success.
Read
Commented by Carsten Mainitz on April 10th, 2026 | 08:20 CEST
Unlocking Massive Potential in Pharma's Largest Segment: Innovator Vidac Pharma, Industry Leader Bayer, or Turnaround Candidate Evotec?
Oncology is the most strategically important growth market in the pharmaceutical industry and at the same time one of the key levers for improving global health. Currently, around 20 million people worldwide are diagnosed with cancer each year, a figure expected to exceed 30 million annually by 2040. The global oncology drug market is already valued at over USD 200 billion and continues to expand rapidly. Bayer aims to rank among the world's leading oncology players by 2030 and recently reaffirmed its medium-term targets. Following the sale of a stake in a cancer specialist, shareholders of Evotec, which has faced significant pressure, may soon benefit from a welcome inflow of funds. Vidac Pharma, on the other hand, is breaking new ground in the fight against skin cancer. There is enormous potential here.
Read
Commented by André Will-Laudien on April 7th, 2026 | 07:35 CEST
Fertilizer Crisis: Supply Chain Collapse Threatens Bayer, Nestlé, MustGrow, and K+S! Where are the Opportunities for Investors?
The escalation involving Iran has thrown global supply chains and the fertilizer and food sectors into a state of emergency, as sanctions and security risks are crippling exports of key raw materials. Iran, a key producer of phosphate-based fertilizers and potash products, is temporarily out of the picture, leading to price spikes of up to 40% in the agricultural sector. Bayer is struggling with rising production costs for its agrochemicals division, which is putting extreme pressure on margins. Even Nestlé is increasingly facing raw material shortages for animal feed and packaging materials. The situation regarding supply security in Europe is at risk in the medium term, as inflationary pressure on food prices is noticeably increasing. MustGrow is positioning itself as a game-changer with organic fertilizer alternatives that are scalable regardless of geopolitical hotspots and promise rapid revenue growth. Kali + Salz is benefiting massively from the demand for potash fertilizer, as European inventories shrink and demand from agriculture explodes.
Read
Commented by André Will-Laudien on March 25th, 2026 | 09:35 CET
Oil Volatility Shakes Markets – Life Sciences Stocks Back in Focus: Bayer, Vidac Pharma, Valneva, Novo Nordisk, and Pfizer
The conflicts in the Middle East continue. With the first talks between the US and Iran, the stock markets made a lightning-fast upward adjustment. As a result, the German benchmark index DAX 40 gained a full 1,600 points within just 10 minutes at the start of the week. However, it was unable to hold that level, falling back to 22,600 points yesterday. The question now is whether the parties to the conflict can actually reach a viable solution. Completely unfazed by the broader market conditions, some news is making waves in the life sciences sector, driving price movements here and there. It is good to shift the focus away from daily market fluctuations and toward other profitable sectors. Here are a few ideas.
Read
Commented by Mario Hose on March 25th, 2026 | 07:00 CET
The Mustard Revolution Is Here! How the Newcomer MustGrow Is Challenging Giants Bayer and K+S
We may already be, or soon find ourselves, at a dangerous crossroads in world history, where the mere availability of food becomes a decisive factor of power. While headlines are dominated by blocked shipping routes like the Strait of Hormuz and fertilizer shortages, a new alliance for supply security is forming on the stock market. Companies such as Bayer and K+S find themselves in a technical chart situation that raises only one key question: Is this a good entry opportunity? At the same time, the innovative pioneer MustGrow Biologics is preparing to disrupt the market from the ground up with its patented mustard-based technology. In this report, we analyze why the combination of established chemical power, strategic raw materials, fertilizers, and a biological revolution could stabilize your portfolio right now. Those who fail to take a closer look may miss the moment when the course for the coming years is set.
Read
Commented by Armin Schulz on March 20th, 2026 | 08:20 CET
Fertilizer Crisis Triggered by the Iran War: Why Bayer, MustGrow Biologics, and K+S Offer the Perfect Portfolio Mix
When bombs fall in the Persian Gulf, the global agricultural economy trembles. The recent military strikes against Iran have thrown the fertilizer markets into turmoil. Prices for nitrogen and ammonia are skyrocketing, and shares of North American corporations are surging by double digits. Regardless of the acute geopolitical upheaval, the industry is undergoing a fundamental transformation. While one half of the sector is still cashing in on the short-term gains from the crisis, the other has long been driving forward the vision of sustainable agriculture, spurred by regulatory pressure. Three companies show where the journey is headed: agricultural giant Bayer, agricultural biotechnology company MustGrow Biologics, and fertilizer specialist K+S.
Read
Commented by Armin Schulz on March 11th, 2026 | 07:20 CET
Three trends, one goal: How Bayer, MustGrow Biologics, and BASF are turning the agricultural revolution into a profit opportunity
Three trends are currently driving the global agricultural economy: skyrocketing fertilizer prices, regulatory pressure to preserve biodiversity, and the insatiable hunger of a growing population. As farmers navigate between existential fears and the pressure to go green, a billion-dollar transformation of industry is looming. Old chemistry is reaching its limits, while demand for biological alternatives and precision technologies is reaching an all-time high. Amid this tension between volatility and opportunity, the future of plant production is being reshaped. We take a look at how Bayer, MustGrow Biologics, and BASF are driving this transformation and could benefit from it.
Read
Commented by Fabian Lorenz on March 6th, 2026 | 07:20 CET
SHORT SQUEEZE at Gerresheimer? Will Bayer and MustGrow soon grow together?
While the stock market digests the Iran war and rising energy prices, Gerresheimer's share price is suddenly rising noticeably. There is no news. Is a short squeeze possible? Short sellers had even expanded their positions recently. Bayer does not (yet) hold a stake in MustGrow. However, the Leverkusen-based company has acquired a license to distribute the innovative agricultural products and is investing in their approval. This could enable MustGrow shares to make the leap from hidden gem to high flyer. Management has recently expressed optimism. The stock appears to be undervalued. After the sharp setback in recent weeks, analysts see upside potential for Bayer again. However, shareholders should not expect much in terms of revenue and profit growth in the current year. Cash flow is even expected to be significantly negative.
Read